Last updated: February 14, 2026
Overview of the Drug
NDC 62135-0067 is identified as Tremfya (guselkumab), a monoclonal antibody developed by Janssen Pharmaceuticals. It is approved for moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Tremfya's mechanism involves inhibiting interleukin-23 (IL-23), which reduces inflammation linked to autoimmune conditions.
Market Landscape
Market Size and Growth
Janssen's Tremfya holds a significant position in the biologic psoriasis market. The global psoriasis treatment market was valued at approximately $15 billion in 2022, predicted to grow at a compound annual growth rate (CAGR) of 8% through 2028. The biologic segment accounts for roughly 70% of this market, driven by increasing prevalence, expanded indications, and new approval momentum.
Key Competitors
Primary competitors within the IL-23 inhibitor class include:
- Skyrizi (risankizumab) by AbbVie
- Ilumya (tildrakizumab) by Sun Pharmaceutical
- Ilumya (risankizumab) by Boehringer Ingelheim
Other biologics such as Humira (adalimumab) and Cosentyx (secukinumab) also compete in the broader autoimmune indication space but target different pathways.
Market Penetration and Adoption
Tremfya's adoption rate has increased due to its efficacy and dosing convenience (every eight weeks). The drug's market penetration varies by region:
- U.S.: Leading biologic for plaque psoriasis, with approximately 25% of biologic prescriptions.
- Europe: Rapid growth, capturing around 20% of the biologic psoriasis market.
- Emerging Markets: Limited due to pricing and healthcare infrastructure but growing.
Regulatory and Patent Landscape
Janssen secured approval for both psoriasis and psoriatic arthritis in multiple markets starting from 2017. Patent exclusivity extends into the late 2020s, with biosimilar competition expected to enter the market around 2028.
Pricing Analysis
Current Pricing
- U.S. List Price: Approximately $6,600 per dose (based on a 100 mg dose administered every 8 weeks).
- Average Annual Cost: Around $87,000.
- Insurance Reimbursement: Heavy reliance on PBMs and insurance plans; typical out-of-pocket costs can range from $15,000 to $50,000 annually, depending on coverage.
Regional Price Variability
- Europe: Prices are generally lower, ranging from €5,000 to €7,000 per dose, reflecting national healthcare policies.
- Emerging Markets: Substantially lower, often subsidized, with prices around $3,000 - $4,000 per dose.
Reimbursement and Access Dynamics
Reimbursement policies tightly control access, often requiring step therapy or prior authorization. Contract negotiations influence net prices, which are often below list prices.
Future Price and Market Projections
Factors Influencing Future Pricing
- Patent Expiry and Biosimilar Entry: Priority consideration is the 2028 patent expiration, which likely will induce pricing competition.
- Market Penetration: Increased adoption among biologic-naïve and switching patients could sustain revenues.
- Regulatory Changes: Price controls in Europe and potential U.S. policies aiming to curb drug spending may erode gross prices.
- Manufacturing and Development Costs: Minimal impact on pricing due to high R&D amortization; manufacturing costs for biologics are high but decreasing with scale.
Price Outlook (Next 5 Years)
- U.S.: Expect marginal price stability around $6,500–$7,000 per dose until patent expiration. Widespread biosimilar entry may reduce net prices by 20-40%.
- Europe and Other Regions: Prices will adjust to local policies, with potential decreases of 10-15%, especially post-patent expiry.
- Emerging Markets: Prices may decline further, impacted heavily by generic biosimilar competition and local health budgets.
Revenue Forecast
- 2023-2025: Revenue estimated between $2.5 billion and $3 billion annually, driven by ongoing market penetration.
- Post-2028: Revenue could decline by 40-60% due to biosimilar competition, unless Janssen develops next-generation biologics or expands indications.
Regulatory and Policy Impacts
- U.S. policy draft proposals aim for price negotiation models through Medicare and private insurers.
- European nations continue to implement cost-effectiveness evaluations influencing list prices.
- Biosimilar approval pathways are well-established, with initial biosimilar approvals in Europe by 2023.
Key Takeaways
- NDC 62135-0067, Tremfya, holds a leading position in the psoriasis biologics market, with strong efficacy and dosing convenience.
- The current U.S. list price is approximately $6,600 per dose, translating into annual costs around $87,000.
- Market competition from newer IL-23 inhibitors and biosimilars will influence pricing dynamics, with significant price reductions expected post-2028.
- Regional pricing varies notably, with higher prices in the U.S. and Europe, and lower prices in emerging markets.
- The drug's revenue is projected to peak before 2028, then decline sharply with biosimilar entry.
FAQs
1. When will biosimilars for Tremfya become available?
Biosimilar versions are expected post-2028, aligned with patent expiration in the U.S. and Europe.
2. How does Tremfya compare in efficacy to competitors?
Clinical trials show Tremfya achieves higher clearance rates than some competitors, with approximately 80% of patients achieving PASI 90 after 16 weeks.
3. What is the typical insurance coverage for Tremfya?
Insurance coverage heavily depends on the provider and region; prior authorization and step therapy are common practices limiting access until approved.
4. How are price controls affecting biologic pricing globally?
European countries implement health technology assessments influencing prices, often resulting in discounts up to 20%. Emerging regions see pressures to lower prices through negotiations and local policies.
5. What are the strategies for maintaining revenue as biosimilars enter the market?
Janssen may introduce next-generation biologics, expand indications, and emphasize patient convenience and efficacy to retain market share.
References
[1] IQVIA, "Global Biosimilars Market Report," 2022.
[2] EvaluatePharma, "Biologic Market Outlook," 2022.
[3] Janssen, "Tremfya (guselkumab) Product Label," 2022.
[4] CDC, "Psoriasis Prevalence and Treatment Trends," 2022.
[5] U.S. FDA, "Biosimilar Approval Timeline," 2023.
